Daisuke Utsumi
University of the Ryukyus
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Daisuke Utsumi.
International Journal of Cancer | 2014
Hiroko Fujii; Akiko Arakawa; Daisuke Utsumi; Shinji Sumiyoshi; Yosuke Yamamoto; Akihiko Kitoh; Masahiro Ono; Yumi Matsumura; Mayumi Kato; Keisuke Konishi; Takeo Shiga; Shigetoshi Sano; Shimon Sakaguchi; Aya Miyagawa-Hayashino; Kenzo Takahashi; Hiroshi Uezato; Yoshiki Miyachi; Miki Tanioka
Tumor‐infiltrating lymphocytes (TILs) have been reported as a prognostic factor in various cancers and are a promising target for immunotherapy. To investigate whether TILs have any impact on the prognosis of angiosarcoma patients, 55 non‐treated patients (40 patients at stage 1 with cutaneous localized tumors, 4 patients at stage 2 with lymph node metastases and 11 patients at stage 3 with distant metastases) with angiosarcoma were evaluated retrospectively by immunohistochemistry stained CD4, CD8, FOXP3 and Ki67. The Kaplan–Meier method was used to estimate overall survival with patients at stage 1. Survival differences were analyzed by the log‐rank test. Patients with higher numbers of CD8+ TILs in their primary tumors survived significantly longer compared with patients with lower values. Moreover, the number of CD8 in TILs was positively correlated with a distant metastasis‐free period. The total number of primary TILs (CD4 plus CD8) and CD8+ primary TILs of stage 3 patients with distant metastases was positively correlated with their overall survival. To evaluate whether CD8+ effector T cells are activated or differentiated, flow cytometric analysis of peripheral blood mononuclear cells (PBMC) was performed. The percentages of CD8+ T cells producing IFN‐γ in PBMC were significantly higher in patients with angiosarcoma (n = 10) compared not only with that of healthy controls (n = 20) but also patients with advanced melanoma (n = 11). These results suggest that anti‐tumor immunity is clinically relevant in angiosarcoma.
The Journal of Infectious Diseases | 2017
Ryoko Awazawa; Daisuke Utsumi; Harutaka Katano; Tsuyoshi Awazawa; Takuya Miyagi; Kentaro Hayashi; Shigetaka Matori; Hiroshi Uezato; Kenzo Takahashi
Background Non-acquired immune deficiency syndrome (AIDS) Kaposis sarcoma (KS) is extremely rare in Japan but highly endemic in Okinawa, especially in Miyako Islands. We aimed to elucidate the exact incidence and cause of this high prevalence. Methods Non-AIDS KS cases in Okinawa Prefecture over the past 31 years were reviewed, and human herpesvirus 8 (HHV8) seroprevalence in Miyako Islands was determined. We examined whole-genome sequences of 3 HHV8 strains and performed whole-exome sequencing of 4 male patients from Miyako Islands. Results Approximately half of the non-AIDS KS cases in Okinawa Prefecture were from Miyako Islands. The age-adjusted incidence rate was 0.87/105 per year for Miyako Islands and 0.056/105 per year for the rest of Okinawa. Human herpesvirus 8 seroprevalence was 15.4% in Miyako Islands. The 3 HHV8 genomes isolated from Miyako islanders formed a phylogenetically branch distinct from those of previously sequenced HHV8 strains and shared specific mutations in 9 proteins. These mutations were verified in Okinawan patients other than those from Miyako Islands. Whole-exome sequencing of the 4 male Miyako Islanders did not reveal shared pathogenic mutations. Conclusions Miyako Islands are an endemic area of non-AIDS KS. The high rate of a distinct HHV8 may contribute to the high incidence of KS in the region.
Journal of Global Oncology | 2017
Akira Shimizu; Kyoichi Kaira; Yuko Okubo; Daisuke Utsumi; Masahito Yasuda; Takayuki Asao; Masahiko Nishiyama; Kenzo Takahashi; Osamu Ishikawa
Purpose Programmed death-1 (PD-1) or programmed death ligand-1 (PD-L1) targeted therapies have shown promising survival outcomes in several human neoplasms. However, it is unclear whether the expression of PD-L1 can be correlated to any clinical and pathologic variables in patients with cutaneous angiosarcoma (CA). The aim of this study was to evaluate the clinicopathological significance of PD-L1 expression in CA patients. Materials and Methods Data from 52 patients with CA were retrospectively reviewed. PD-L1 expression, tumor proliferation determined by Ki-67 index, and immunohistochemical evaluation of tumor-infiltrating lymphocytes, CD4+ and CD8+, were used to determine correlation with clinicopathological variables. Results PD-L1 was positively expressed in 40% of all patients. PD-L1 expression was significantly associated with tumor cell proliferation. Multivariate analysis confirmed that high levels of CD8+ tumor-infiltrating lymphocytes were a significant predictor in patients with clinical stage I CA and the positive expression of PD-L1 was an independent prognostic factor in predicting worse outcome. Conclusion PD-L1 expression is a novel pathologic marker for predicting worse outcome in patients with CA.
Journal of Dermatology | 2013
Daisuke Utsumi; Fukuko Hanashiro; Takuya Miyagi; Yu-ichi Yamamoto; Hiroshi Uezato; Kenzo Takahashi
eruptions of pemphigoid nodularis. In pemphigoid nodularis, it is postulated that scratching trauma and localized inflammation expose cryptic epitopes within the BMZ, resulting in the development of autoantibodies to BP230 and/or BP180. In the present case, pemphigoid nodularis may have been induced by etanercept. So far, six cases of autoimmune bullous diseases induced by anti-TNF-a agents have been reported. Anti-TNF-a agents may cause selective inhibition of a cytotoxic T-lymphocyte response that normally suppresses autoreactive B cells, resulting in enhanced antibody production. On the other hand, successful treatments of mucous membrane pemphigoid and pemphigus vulgaris with anti-TNF-a agents have also been reported. Thus, a careful clinical and immunological evaluation is recommended during the treatment with anti-TNF-a agents.
Nishi Nihon Hifuka | 2010
Hironori Matsuura; Daisuke Utsumi; Wataru Fujimoto; Hisaharu Mitekura; Kanako Urushihara; Hiroshi Uezato
Journal of Investigative Dermatology | 2018
A. Ohira; Sayaka Yamaguchi; Daisuke Utsumi; Kenzo Takahashi
Journal of Investigative Dermatology | 2018
T. Omine; Daisuke Utsumi; Sayaka Yamaguchi; Kenzo Takahashi
Journal of Investigative Dermatology | 2017
Ryoko Awazawa; Daisuke Utsumi; Harutaka Katano; Kenzo Takahashi
Journal of Investigative Dermatology | 2017
Takuya Miyagi; Yuko Okubo; Sayaka Yamaguchi; Daisuke Utsumi; R. Tanaka; Yuetsu Tanaka; Kenzo Takahashi
Journal of Dermatological Science | 2017
Daisuke Utsumi; Akiko Matsumoto; Ngalla Jillani; Daniel Chai Chivastasi; Atunga Nyachieo; Kenzo Takahashi